STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] ABEONA THERAPEUTICS INC. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Nantahala Capital Management, LLC and two managers report shared beneficial ownership of 5,184,662 shares of Abeona Therapeutics, representing 9.99% of the outstanding common stock as of 09/30/2025. The total includes 619,997 shares that may be acquired within 60 days upon exercise of warrants. Nantahala reports shared voting and dispositive power over these shares; none are held with sole voting or sole dispositive power. The filing states the holdings are managed in the ordinary course of business and not for the purpose of changing control. Contact and organizational details for Nantahala, and certifications by Nantahala and managers Wilmot B. Harkey and Daniel Mack, are included with signatures dated 10/06/2025.

Positive
  • Clear disclosure of total shares (5,184,662) and inclusion of warrant count (619,997)
  • Certification that holdings are in the ordinary course of business and not to change control
Negative
  • Position sits at 9.99%, just below the 10% threshold that would trigger different filings
  • Shared voting/dispositive power only, meaning individual influence is not separated for investors

Insights

Investor group holds just under 10% including near-term warrant exercisable shares.

The combined position of 5,184,662 shares equals 9.99% of outstanding common stock using the issuer's 51,278,539 share base; this calculation expressly includes 619,997 warrant-acquirable shares exercisable within 60 days.

The position is reported as held in the ordinary course of business with shared voting and dispositive power, which implies coordinated portfolio management rather than an explicit control intent; monitor warrant exercises over the next 60 days for any increase in fully-diluted stake.

Reporting persons disclose shared control but deny intent to influence issuer control.

All voting and dispositive power is reported as shared (no sole power), and the filing includes the required certification that the position is not intended to change or influence control of the issuer.

Because the threshold reported is at 9.99%, close to the 10% reporting milestone, any subsequent acquisitions or warrant exercises that push ownership above 10.00% would trigger different filing obligations and merits monitoring over the near term.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Nantahala Capital Management, LLC
Signature:/s/ Taki Vasilakis
Name/Title:Taki Vasilakis / Chief Compliance Officer
Date:10/06/2025
Wilmot B. Harkey
Signature:/s/ Wilmot B. Harkey
Name/Title:Wilmot B. Harkey / Manager
Date:10/06/2025
Daniel Mack
Signature:/s/ Daniel Mack
Name/Title:Daniel Mack / Manager
Date:10/06/2025

FAQ

What stake does Nantahala report in Abeona Therapeutics (ABEO)?

Nantahala reports beneficial ownership of 5,184,662 shares, equal to 9.99% of common stock as of 09/30/2025.

Does the reported stake include exercisable warrants?

Yes, the total includes 619,997 shares that may be acquired within 60 days upon exercise of warrants.

Do the reporting persons claim control of Abeona (ABEO)?

No; the filing states the securities were acquired and are held in the ordinary course of business and not to change or influence control.

Who are the individual reporting persons on behalf of Nantahala?

The filing lists managers Wilmot B. Harkey and Daniel Mack as reporting persons and names Nantahala Capital Management, LLC as the adviser.

When were the signatures dated on this Schedule 13G/A?

Signatures from the reporting persons are dated 10/06/2025.
Abeona Therapeut

NASDAQ:ABEO

ABEO Rankings

ABEO Latest News

ABEO Latest SEC Filings

ABEO Stock Data

228.69M
48.58M
5.78%
73.58%
17.61%
Biotechnology
Pharmaceutical Preparations
Link
United States
CLEVELAND